Synmosa Biopharma (ROCO:4114) Long-Term Capital Lease Obligation : NT$48 Mil (As of Mar. 2025)

View and export this data going back to 2003. Start your Free Trial

What is Synmosa Biopharma Long-Term Capital Lease Obligation?

Synmosa Biopharma's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was NT$48 Mil.

Synmosa Biopharma's quarterly Long-Term Capital Lease Obligation increased from Sep. 2024 (NT$49 Mil) to Dec. 2024 (NT$50 Mil) but then declined from Dec. 2024 (NT$50 Mil) to Mar. 2025 (NT$48 Mil).

Synmosa Biopharma's annual Long-Term Capital Lease Obligation increased from Dec. 2022 (NT$48 Mil) to Dec. 2023 (NT$59 Mil) but then declined from Dec. 2023 (NT$59 Mil) to Dec. 2024 (NT$50 Mil).

Synmosa Biopharma Long-Term Capital Lease Obligation Historical Data

The historical data trend for Synmosa Biopharma's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synmosa Biopharma Long-Term Capital Lease Obligation Chart

Synmosa Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

3.84

6.76

48.42

58.66

49.86

Synmosa Biopharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															53.75	51.32	49.07	49.86	47.78

Synmosa Biopharma (ROCO:4114) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Synmosa Biopharma Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Synmosa Biopharma's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Synmosa Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synmosa Biopharma Corp (ROCO:4114) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 6, Gongye 1st Road, Hukou Township, Hsinchu County, Hsinchu, TWN

Website

https://www.synmosa.com.tw

Synmosa Biopharma Corp is engaged in the research and development, manufacturing, marketing, and distribution of pharmaceutical products, medical devices, cosmetics, animal drugs, chemical food additives, and beverages. It is also involved in manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. The company provides prescription, OTC medicines, and healthcare products under its Synmosa trademark. The reporting segments of the company are; the Generic Drugs segment which derives key revenue, and the Active Pharmaceutical Ingredients segment.

Synmosa Biopharma Headlines

No Headlines